![Dean Schorno](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dean Schorno
Directeur Financier/CFO chez
RIGEL PHARMACEUTICALS, INC.
Fortune : 3 M $ au 30/06/2026
Profil
Dean L.
Schorno is Chief Financial Officer & Executive Vice President at Rigel Pharmaceuticals, Inc. since 2018.
Formerly, Mr. Schorno was Chief Financial Officer & Head-Investor Relations at Genomic Health, Inc. from 2011 to 2014, Chief Financial Officer at Adaptive Biotechnologies Corp.
from 2014 to 2015, and Chief Financial Officer & Head-Operations at 23andMe, Inc. from 2015 to 2018.
Education includes graduate studies at Golden Gate University and undergraduate studies at the University of California, Berkeley.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 17/06/2026 | 78 790 ( 0,43 % ) | 3 M $ | 30/06/2026 |
Postes actifs de Dean Schorno
| Sociétés | Poste | Début |
|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Directeur Financier/CFO | 29/05/2018 |
Anciens postes connus de Dean Schorno
| Sociétés | Poste | Fin |
|---|---|---|
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Directeur Financier/CFO | 01/05/2018 |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Directeur Financier/CFO | 10/08/2015 |
| GENOMIC HEALTH, INC. | Directeur Financier/CFO | 01/07/2014 |
Formation de Dean Schorno
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
49
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Rigel Pharmaceuticals, Inc.
 Rigel Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which discovers, develops and provides novel small-molecule drugs | Health Technology |
Genomic Health, Inc.
 Genomic Health, Inc. Medical/Nursing ServicesHealth Services Engages in genomic-based diagnostic tests for overtreatment and optimal treatment of early stage cancer | Health Services |
Golden Gate University
 Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Health Technology |
Adaptive Biotechnologies Corp.
 Adaptive Biotechnologies Corp. BiotechnologyHealth Technology Develops minimal residual disease and immune medicine | Health Technology |
